Deepinder Goyal’s Temple Unveils First 100 Brain-Monitoring Wearables, Invites Early Users

Deepinder Goyal has taken a bold step into health-tech with his startup Temple, announcing the readiness of its first 100 wearable devices designed to monitor brain activity, as the company begins onboarding its initial users.

Temple Moves from Prototype to Limited Production

Health-tech startup Temple has reached a key milestone by producing its first batch of 100 brain-monitoring wearable devices. This development marks the transition of the company from the experimental prototype phase to early-stage production.

The announcement was made by Deepinder Goyal via a LinkedIn post, where he highlighted that the company is now ready to test its innovation in real-world conditions with a select group of early adopters.

This move signals Temple’s ambition to establish itself in the emerging intersection of wearable technology and cognitive health monitoring.

Startup Invites Founding Users Across Diverse Fields

Temple is actively seeking its first cohort of “founding users,” inviting applications from a wide range of individuals. These include athletes, scientists, doctors, entrepreneurs, creators, and anyone deeply invested in improving their physical and cognitive well-being.

Interested applicants are required to submit basic details such as name, email, phone number, and social media profiles. Additionally, they must provide a short statement explaining their expectations from the device.

The company has stated that selected applicants will be contacted via WhatsApp, suggesting a personalised onboarding process for early users.

This selective approach reflects Temple’s intention to gather meaningful feedback from individuals who can rigorously test the product and contribute to its refinement.

A Unique Wearable Focused on Brain Health Metrics

Temple’s wearable device stands out due to its focus on measuring cerebral blood flow in real time—a metric that is not currently tracked by mainstream consumer wearables.

Unlike traditional fitness trackers that monitor heart rate, sleep, or activity levels, Temple aims to provide insights into brain health, potentially opening new avenues in preventive healthcare and performance optimisation.

The company claims that its technology could help users better understand how lifestyle, posture, and daily habits impact cognitive function.

The ‘Gravity Ageing Hypothesis’ Behind the Innovation

The concept behind the device is rooted in Deepinder Goyal’s “gravity ageing hypothesis.”

This theory suggests that prolonged upright posture over time may reduce blood flow to the brain, potentially contributing to ageing-related cognitive decline.

By tracking cerebral blood flow, the wearable aims to provide actionable insights that could help users mitigate such effects through posture correction, movement, or other interventions.

While the hypothesis is intriguing, it remains a subject of debate within the scientific community, and further validation will be essential for broader acceptance.

Funding Boost Strengthens Temple’s Growth Plans

The announcement comes shortly after Temple secured $54 million in a friends-and-family funding round, valuing the company at approximately $190 million post-money.

The round saw participation from:

• Founder acquaintances
• Early investors from Zomato
• Over 30 employees of Temple

This funding provides the startup with the resources needed to scale production, enhance research and development, and refine its product offering.

Leadership Transition at Eternal and Strategic Shift

Earlier this year, Deepinder Goyal stepped down as Managing Director and Group CEO of Eternal, the parent company of Zomato and Blinkit.

He transitioned into the role of Vice Chairman to focus on high-risk innovation projects like Temple.

Following this move, Albinder Dhindsa assumed the position of Group CEO at Eternal, marking a leadership shift aimed at driving operational stability while Goyal explores new ventures.

Controversy Around Hiring Practices

Temple had previously drawn public attention in February due to its unconventional hiring criteria.

A job posting by the company required engineering applicants to meet specific body fat percentage thresholds—below 16% for men and 26% for women. This requirement sparked widespread debate on social media, with critics questioning its relevance and inclusivity.

While the company did not provide detailed clarification, the incident highlighted the intense scrutiny faced by emerging startups, particularly those led by high-profile entrepreneurs.

Unanswered Questions: Pricing and Clinical Validation

Despite the excitement surrounding the product, several key details remain undisclosed.

Temple has not yet revealed:

• The pricing of the wearable
• A timeline for commercial launch
• Clinical validation data supporting its claims

Medical experts have expressed skepticism about whether a skin-mounted wearable can accurately measure deep cerebral blood flow outside controlled clinical environments.

Such concerns underscore the importance of rigorous testing and validation before the device can achieve mainstream adoption.

Potential Impact on Health-Tech and Wearables Market

If successful, Temple’s device could redefine the scope of consumer wearables by shifting the focus from general fitness tracking to advanced cognitive health monitoring.

This could open new possibilities in:

• Preventive healthcare
• Mental performance optimisation
• Personalised wellness strategies

However, the company will need to overcome scientific, regulatory, and market adoption challenges to realise this vision.

Conclusion

The unveiling of the first 100 wearable devices by Temple marks an important step in its journey toward redefining health-tech innovation. Led by Deepinder Goyal, the startup is venturing into uncharted territory by attempting to bring brain health monitoring into everyday consumer technology. While the concept holds significant promise, its long-term success will depend on scientific validation, user adoption, and the ability to address skepticism within the medical community.